ReviewFrontiers in immunology2019
The Long Pentraxin PTX3 as a Humoral Innate Immunity Functional Player and Biomarker of Infections and Sepsis.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 3 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- Are There Non-Invasive Biomarker(s) That Would Facilitate the Detection of Ovarian Torsion? A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2024Pooled it
- The Prognostic Value of Pentraxin-3 in COVID-19 Patients: A Systematic Review and Meta-Analysis of Mortality Incidence.International journal of molecular sciences · 2023Pooled it
- Pentraxin-3 as a predictive marker of mortality in sepsis: an updated systematic review and meta-analysis.Critical care (London, England) · 2022Pooled it
- Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia.Frontiers in immunology · 2020Trial
- Muscle loss and pentraxin-3 as predictors of immunotherapy outcomes in non-small cell lung cancer: a prospective study.Scientific reports · 2026Article
- Diagnostic value of pentraxin 3 in plasma and bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in non-neutropenic patients: a prospective multicenter clinical study.Emerging microbes & infections · 2026Article
- The interplay between recovery and immunity in infectious and non-communicable diseases.Frontiers in cellular and infection microbiology · 2026Review
- Association of Umbilical Cord Blood P-Selectin and PTX3 Levels with Early-Onset Sepsis in Preterm Infants with Premature Rupture of Membranes.International journal of general medicine · 2026Article
- A Correlation between Sequential Organ Failure Assessment Scores and Biomarkers of Inflammation and Infection in Patients with Sepsis.Current medicinal chemistry · 2026Article
- Host-derived immune signatures as biomarkers to differentiate arboviral acute febrile illness from other causes of acute fever.Frontiers in microbiology · 2026Article
- Pentraxin-3 in thyroid nodules: a systemic marker of pathology and a local mediator of inflammation and carcinoma.Frontiers in endocrinology · 2026Article
- Pentraxin 3 Levels Reflect Inflammatory and Parasitic Activity in Human Visceral Leishmaniasis.Pathogens (Basel, Switzerland) · 2025Observational
- The natural immune molecules urinary Tamm-Horsfall protein and pentraxin 3 as predictors for recurrent urinary tract infection severity: a single-center self-control study.Renal failure · 2025Article
- High-density lipoproteins. Part 2. Impact of disease states on functionality.American journal of preventive cardiology · 2025Article
- Potential role of pentraxin 3 (PTX3) and aldehyde dehydrogenase (ALDH) in liver cirrhotic patients: predicting and diagnostic impact in hepatocellular carcinoma (HCC) development.Molecular biology reports · 2025Article
- Potential auxiliary diagnostic role of pentraxin 3 in plasma and bronchoalveolar lavage fluid for pulmonary tuberculosis.Journal of cardiothoracic surgery · 2025Article
- Pentraxin 3 as a Prognostic Biomarker in Aneurysmal Subarachnoid Hemorrhage.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Current Prognostic Biomarkers for Peripheral Arterial Disease: A Comprehensive Systematic Review of the Literature.Metabolites · 2025Review
- The effect of therapeutic plasma exchange on the inflammatory response in septic shock: a secondary analysis of the EXCHANGE-1 trial.Intensive care medicine experimental · 2025Article
- Regulated cell death and DAMPs as biomarkers and therapeutic targets in normothermic perfusion of transplant organs. Part 1: their emergence from injuries to the donor organ.Frontiers in transplantation · 2025Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first line of defense in innate immunity is provided by cellular and humoral mediators. Pentraxins are a superfamily of phylogenetically conserved humoral mediators of innate immunity. PTX3, the first long pentraxin identified, is a soluble pattern recognition molecule rapidly produced by several cell types in response to primary pro-inflammatory signals and microbial recognition. PTX3 acts as an important mediator of innate immunity against pathogens of fungal, bacterial and viral origin, and as a regulator of inflammation, by modulating complement activation and cell extravasation, and facilitating pathogen recognition by myeloid cells. In sepsis, PTX3 plasma levels are associated with severity of the condition, patient survival, and response to therapy. In combination with other established biomarkers, PTX3 could improve stratification of sepsis patients and thus, complement the system of classification and monitoring of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.